← Leaderboards
Michael Borchers
Cincinnati Va Medical Center Research
$7,458,552
Attributed
$7,458,552
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $567.8K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,458,552 · 6
VA$0 · 2
By mechanism
R01$6,936,635 · 4
R21$431,750 · 1
F32$90,167 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungMorbidity - Disease RateReceptorLigandsCytokinePathway InteractionsLeadInflammationExhibitsMolecularTissuesDisease ProgressionBaseResponsePathologyImmune FunctionPathogenesisMortalityProductionCellsInsightLymphocytePhenotypeCytotoxicity
Grant awards (29)
Molecular and Cellular Pathogenesis of Pulmonary Langerhans Cell Histiocytosis$541,803
R01 · FY2025 · HL · contact PI
Molecular and Cellular Pathogenesis of Pulmonary Langerhans Cell Histiocytosis$530,966
R01 · FY2024 · HL · contact PI
Natural Killer Cell Subpopulations in COPD Exacerbations$0
I01 · FY2024 · VA · contact PI
Molecular and Cellular Pathogenesis of Pulmonary Langerhans Cell Histiocytosis$567,803
R01 · FY2023 · HL · contact PI
Natural Killer Cell Subpopulations in COPD Exacerbations$0
I01 · FY2023 · VA · contact PI
Natural Killer Cell Functions in Lymphangioleiomyomatosis$399,950
R01 · FY2022 · HL · contact PI
Natural Killer Cell Subpopulations in COPD Exacerbations$0
I01 · FY2022 · VA · contact PI
Natural Killer Cell Functions in Lymphangioleiomyomatosis$399,950
R01 · FY2021 · HL · contact PI
Natural Killer Cell Subpopulations in COPD Exacerbations$0
I01 · FY2021 · VA · contact PI
Natural Killer Cell Functions in Lymphangioleiomyomatosis$399,950
R01 · FY2020 · HL · contact PI
Natural Killer Cell Functions in Lymphangioleiomyomatosis$414,438
R01 · FY2019 · HL · contact PI
Natural Killer Cell Functions in COPD$0
I01 · FY2018 · VA · contact PI
Clec5a regulation of Macrophage function in COPD$395,000
R01 · FY2017 · HL · contact PI
Natural Killer Cell Functions in COPD$0
I01 · FY2017 · VA · contact PI
Clec5a regulation of Macrophage function in COPD$395,000
R01 · FY2016 · HL · contact PI
Natural Killer Cell Functions in COPD$0
I01 · FY2016 · VA · contact PI
Clec5a regulation of Macrophage function in COPD$389,382
R01 · FY2015 · HL · contact PI
Natural Killer Cell Functions in COPD$0
I01 · FY2015 · VA · contact PI
Clec5a regulation of Macrophage function in COPD$396,250
R01 · FY2014 · HL · contact PI
Novel Reagents in Mouse Models of Autoimmune COPD$196,250
R21 · FY2012 · HL · contact PI
Novel Reagents in Mouse Models of Autoimmune COPD$235,500
R21 · FY2011 · HL · contact PI
Shared Mechanisms of Pulmonary Lymphocyte Activation by Bacteria and Toxicants$378,709
R01 · FY2010 · ES · contact PI
Shared Mechanisms of Pulmonary Lymphocyte Activation by Bacteria and Toxicants$382,507
R01 · FY2009 · ES · contact PI
Shared Mechanisms of Pulmonary Lymphocyte Activation by Bacteria and Toxicants$382,473
R01 · FY2008 · ES · contact PI
Shared Mechanisms of Pulmonary Lymphocyte Activation by Bacteria and Toxicants$457,915
R01 · FY2007 · ES · contact PI
Shared Mechanisms of Pulmonary Lymphocyte Activation by Bacteria and Toxicants$504,539
R01 · FY2006 · ES · contact PI
GQ SIGNALING IN EOSINOPHIL RECRUITMENT/ACTIVATION$17,555
F32 · FY2002 · HL
GQ SIGNALING IN EOSINOPHIL RECRUITMENT/ACTIVATION$40,196
F32 · FY2001 · HL
GQ SIGNALING IN EOSINOPHIL RECRUITMENT/ACTIVATION$32,416
F32 · FY2000 · HL